Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.

Pasqua MR, Tsoukas MA, Haidar A

Diabetes, obesity & metabolism27 Oct 2025Cited by 4 (Europe PMC)

PMID41144928PMCIDPMC12673448DOI10.1111/dom.70213PepBankPUB-41144928

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on pump therapy, daily total insulin was significantly reduced from day 7 after starting semaglutide and stayed lower.
In plain wordsIn adults with type 1 diabetes on insulin pumps, daily insulin needs fell from day 7 after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseDaily total insulin
Study
n = 26
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Source sentences
Summary
Daily total and bolus insulin, along with carbohydrate input, were significantly reduced by day 7 and remained so, while basal was significantly reduced by day 32.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492801
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on pump therapy, daily bolus insulin was significantly reduced from day 7 after starting semaglutide and stayed lower.
In plain wordsIn adults with type 1 diabetes on insulin pumps, mealtime insulin doses fell from day 7 after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseDaily bolus insulin
Study
n = 26
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Source sentences
Summary
Daily total and bolus insulin, along with carbohydrate input, were significantly reduced by day 7 and remained so, while basal was significantly reduced by day 32.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492802
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on pump therapy, carbohydrate input was significantly reduced from day 7 after starting semaglutide and stayed lower.
In plain wordsIn adults with type 1 diabetes on insulin pumps, entered carbohydrate amounts fell from day 7 after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseCarbohydrate input
Study
n = 26
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Source sentences
Summary
Daily total and bolus insulin, along with carbohydrate input, were significantly reduced by day 7 and remained so, while basal was significantly reduced by day 32.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492803
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on pump therapy, daily basal insulin was significantly reduced by day 32 after starting semaglutide.
In plain wordsIn adults with type 1 diabetes on insulin pumps, background insulin doses fell by day 32 after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseDaily basal insulin
Study
n = 26
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Source sentences
Summary
Daily total and bolus insulin, along with carbohydrate input, were significantly reduced by day 7 and remained so, while basal was significantly reduced by day 32.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492804
05HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on pump therapy, the median carbohydrate ratio rose by day 77 of semaglutide treatment.
In plain wordsIn adults with type 1 diabetes on insulin pumps, the carbohydrate ratio setting rose by day 77 of semaglutide treatment.
Peptide
Semaglutide
Outcome
IncreaseCarbohydrate ratio at day 77
Study
n = 26
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Measurements
Median increase in carbohydrate ratio
4.1%
day 77
Source sentences
Summary
By day 77, there was a median increase in carbohydrate ratios by 4.1% [-1.8, 7.7]
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492805
06HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on pump therapy, the median correction factor rose by day 77 of semaglutide treatment.
In plain wordsIn adults with type 1 diabetes on insulin pumps, the correction factor setting rose by day 77 of semaglutide treatment.
Peptide
Semaglutide
Outcome
IncreaseCorrection factor at day 77
Study
n = 26
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Measurements
Median increase in correction factor
11.2%
day 77
Source sentences
Summary
and in correction factors by 11.2% [0.0, 20.8]
3 context sentences(design, population, supporting numbers)
Summary · context
By day 77, there was a median increase
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492806
07HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on pump therapy, the median pre-programmed basal rate fell by day 77 of semaglutide treatment.
In plain wordsIn adults with type 1 diabetes on insulin pumps, the programmed background insulin rate fell by day 77 of semaglutide treatment.
Peptide
Semaglutide
Outcome
DecreasePre-programmed basal rates at day 77
Study
n = 26
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Source sentences
Summary
and a reduction in pre-programmed basal rates by 7.9% [-12.7, -4.2]
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492807
08HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes on pump therapy, median time spent in hypoglycemia was rarely above 4% during follow-ups on semaglutide.
In plain wordsIn adults with type 1 diabetes on insulin pumps, time spent with low blood sugar was rarely above 4% during semaglutide follow-up.
Peptide
Semaglutide
Outcome
Not applicableTime in hypoglycemia
Study
n = 26
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1 mg · 11 weeksAs given in this study (human).
Source sentences
Summary
The median time spent in hypoglycemia was rarely >4% during these follow-ups.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post-hoc analysis of a double-blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID).
Summary · context
Twenty-six participants were included; 100% were using CGM and 81% using AID at baseline.
Report a problemFND-4114492808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords